A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-07146-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, 2026. Verfasst von Andrea Duminuco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy. andrea.duminuco@unict.it. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Hematopoiesis, Extramedullary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Catania.
Abstract (Originalsprache)
Extramedullary hematopoiesis (EMH) in myelofibrosis manifests beyond classical splenomegaly, causing life-threatening complications, yet lacks systematic characterization in the JAK inhibitor era. We systematically reviewed 36 publications (2011–2025), available on PubMed database, reporting 47 unique myelofibrosis-associated EMH cases, analyzing demographics, anatomic distribution, presentations, diagnostics, treatments, and outcomes. Median age was 68 years (range 43–82; M: F 26:21); primary myelofibrosis predominated (64%). EMH favored atypical sites: abdominopelvic (28%), thoracic (26%; pulmonary/pleural), serosal (17%), cutaneous (13%). Symptomatic onset occurred in 75% (dyspnea 28%, abdominal pain 21%). CT/MRI revealed characteristic lobulated masses with T2 hypointensity; biopsy confirmed trilineage hematopoiesis with atypical megakaryocytes (CD61+). Ruxolitinib-based regimens, administered in 19 patients (40%) as EMH-directed therapy, yielded rapid palliation (dyspnea/ascites resolution), complemented by radiotherapy (11%) and splenectomy; HSCT achieved complete remission in one case. Mortality reached 38% (median follow-up 5 months), driven by EMH-related organ failure or AML transformation. Atypical EMH signals advanced myelofibrosis with dismal prognosis, responsive to JAK inhibitors/locoregional therapies but highlighting sanctuary biology. Systematic surveillance and transplant referral are imperative; prospective registries are needed to refine risk models and test novel antifibrotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy. andrea.duminuco@unict.it.
- Hematology with BMT Unit, A.O.U. "G. Rodolico-San Marco", Catania, Italy. andrea.duminuco@unict.it.
- Hematology with BMT Unit, A.O.U. "G. Rodolico-San Marco", Catania, Italy.
- Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
ORCID-Profile: Andrea Duminuco
Förderung
- Università degli Studi di Catania
Zitieren
APA
Duminuco, A., Vecchio, V., Lavenia, G., Harrington, P., Santisi, A., Sbriglione, A., & Palumbo, G. A. (2026). A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications. Annals of Hematology. https://doi.org/10.1007/s00277-026-07146-2
Vancouver
Duminuco A, Vecchio V, Lavenia G, Harrington P, Santisi A, Sbriglione A, et al. A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications. Annals of Hematology. 2026. doi:10.1007/s00277-026-07146-2
BibTeX
@article{Duminuco2026,
author = {Duminuco, Andrea and Vecchio, Veronica and Lavenia, Giulio and Harrington, Patrick and Santisi, Annalisa and Sbriglione, Arianna and Palumbo, Giuseppe A},
title = {A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07146-2}
}
EUVIMED